Dexcom Inc

Dexcom’s CGM tech proves reliable in a Swiss insulin‑patch pilot, delivering accurate real‑time glucose data with no failures – a key step for integrated diabetes care.

Dexcom’s Q2/Q3 2025 earnings reveal steady revenue growth, margin improvement, and robust R&D, but investor sentiment warns of pricing, reimbursement, and competition risks.

Dexcom’s quiet institutional selling, amid a booming CGM market, raises questions before its Q1 2026 earnings—will the stock’s growth momentum hold or shift?

Dexcom’s new Eversense 365 CGM shows year‑long glycemic control, driving stock gains and highlighting its role in diabetes care innovation and global expansion.

Explore how Dexcom’s 15‑day CGM, Medicare expansion, and AI features are reshaping diabetes care within the booming digital‑biomarker market.

Dexcom’s recent earnings miss spiked a sharp share‑price drop, but long‑term CGM growth and historic returns hint the stock may still be undervalued and worth watching.

Dexcom’s recent institutional buying surge shows growing confidence in its CGM dominance and strong growth prospects—learn how new capital inflows could signal a short‑term rally.

Dexcom Inc. (DXCM) tops the CGM market with growing sales of G6 and G7 systems, strong 52‑week range, and a “Buy” rating – a smart long‑term health‑tech investment.

Dexcom faces class‑action suits over alleged misstatements, but analysts lift its target to $78 while investors weigh joining lawsuits and market shifts.

Explore how DexCom’s latest securities‑fraud class action and mixed analyst ratings shape investor decisions and potential stock recovery.